Cryoport, Inc.: management transactions · United States · SEC (Form 4)

About Cryoport, Inc.

Cryoport, Inc. (NASDAQ: CYRX) is a specialized life sciences supply-chain company headquartered in Brentwood, Tennessee, United States. Founded in 1999, it has evolved from a logistics-focused business into an integrated platform serving biopharmaceutical, animal health, and human reproductive medicine markets. For investors, Cryoport should be viewed less as a traditional transporter and more as mission-critical infrastructure for temperature-sensitive and high-value biological products. The company’s core business centers on temperature-controlled logistics, cryogenic and ultra-cold shipping systems, bio-storage, and related services for advanced therapies. Its platform supports cell and gene therapy developers, biologics manufacturers, clinical trial programs, and other sensitive life-science applications. Over time, Cryoport has broadened its offering beyond shipping into cryopreservation, biostorage, packaging, labeling, kit production, and logistics orchestration. That broader scope increases wallet share and makes the company more embedded in customer workflows. Cryoport’s competitive positioning is built on specialization, compliance, and operational reliability. In advanced therapies, where product integrity and chain-of-custody are essential, the company’s expertise in regulated, temperature-controlled supply chains creates meaningful barriers to entry. Its value proposition is tied to reducing risk for customers running complex global programs, especially in cell and gene therapy, where a logistics failure can destroy a high-value batch. The group emphasizes its global reach across the Americas, EMEA, and APAC, with more than 50 strategic locations and a customer base exceeding 3,000 worldwide. Recent developments underline the company’s strategic expansion. In June 2024, Cryoport officially launched its Global Supply Chain Hub in Stevenage, U.K., strengthening its European footprint. In January 2025, it announced a strategic partnership with Moffitt Cancer Center to establish a state-of-the-art biorepository center in Florida. Its 2024 annual report also showed continued traction in its core market, with 701 clinical trials supported globally at year-end 2024, including 81 phase 3 trials. More broadly, Cryoport remains a growth-oriented platform leveraged to the expansion of advanced therapies, but its investment case depends on execution, commercial adoption in cell and gene therapy, and the company’s ability to translate its international footprint into durable profitability.